CEOP-IMVP-Dexa regimen
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated…
We retrospectively analyzed our chemotherapy results in patients with the Acquired Immunodeficiency Virus syndrome (AIDS) and…
Primary end point of this trial was to reduce neutropenic infections during the treatment of aggressive NHL with CEOP/IMVP-Dexa…
PURPOSE
This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter…
We report on a 28 year old Turkish woman, who was admitted to our hospital with the symptoms of malabsorption and protein-loosing…
A combination of two non‐cross‐resistant regimens, CEOP and IMVP‐Dexa given every 4 weeks, three to six times according to…